Margarita Souleimanova
Overview
Explore the profile of Margarita Souleimanova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez-Cuadrado L, Bullock E, Mabruk Z, Zhao H, Souleimanova M, Noer P, et al.
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205651
Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer, and it exhibits a number of clinico-pathological characteristics distinct from the more common invasive ductal carcinoma...
2.
Yu G, Li X, He T, Gruosso T, Zuo D, Souleimanova M, et al.
Front Physiol
. 2020 Oct;
11:511071.
PMID: 33071806
The abundance and/or location of tumor infiltrating lymphocytes (TILs), especially CD8 T cells, in solid tumors can serve as a prognostic indicator in various types of cancer. However, it is...
3.
Savage P, Pacis A, Kuasne H, Liu L, Lai D, Wan A, et al.
Commun Biol
. 2020 Jun;
3(1):310.
PMID: 32546838
Subsets of breast tumors present major clinical challenges, including triple-negative, metastatic/recurrent disease and rare histologies. Here, we developed 37 patient-derived xenografts (PDX) from these difficult-to-treat cancers to interrogate their molecular...
4.
Gruosso T, Gigoux M, Manem V, Bertos N, Zuo D, Perlitch I, et al.
J Clin Invest
. 2019 Feb;
129(4):1785-1800.
PMID: 30753167
Understanding the tumor immune microenvironment (TIME) promises to be key for optimal cancer therapy, especially in triple-negative breast cancer (TNBC). Integrating spatial resolution of immune cells with laser capture microdissection...
5.
Robichaud N, Hsu B, Istomine R, Alvarez F, Blagih J, Ma E, et al.
Proc Natl Acad Sci U S A
. 2018 Feb;
115(10):E2202-E2209.
PMID: 29463754
The translation of mRNAs into proteins serves as a critical regulatory event in gene expression. In the context of cancer, deregulated translation is a hallmark of transformation, promoting the proliferation,...
6.
Saleh S, Bertos N, Gruosso T, Gigoux M, Souleimanova M, Zhao H, et al.
Cancer Res
. 2017 Jun;
77(17):4673-4683.
PMID: 28652250
Triple-negative breast cancer (TNBC) is a molecularly heterogeneous cancer that is difficult to treat. Despite the role it may play in tumor progression and response to therapy, microenvironmental (stromal) heterogeneity...
7.
Tofigh A, Suderman M, Paquet E, Livingstone J, Bertos N, Saleh S, et al.
Cell Rep
. 2014 Oct;
9(1):129-142.
PMID: 25284793
Breast carcinoma (BC) has been extensively profiled by high-throughput technologies for over a decade, and broadly speaking, these studies can be grouped into those that seek to identify patient subtypes...
8.
Pepin F, Bertos N, Laferriere J, Sadekova S, Souleimanova M, Zhao H, et al.
Breast Cancer Res
. 2012 Aug;
14(4):R120.
PMID: 22906178
Introduction: Angiogenesis represents a potential therapeutic target in breast cancer. However, responses to targeted antiangiogenic therapies have been reported to vary among patients. This suggests that the tumor vasculature may...
9.
Ponzo M, Lesurf R, Petkiewicz S, OMalley F, Pinnaduwage D, Andrulis I, et al.
Proc Natl Acad Sci U S A
. 2009 Jul;
106(31):12903-8.
PMID: 19617568
Elevated MET receptor tyrosine kinase correlates with poor outcome in breast cancer, yet the reasons for this are poorly understood. We thus generated a transgenic mouse model targeting expression of...
10.
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al.
Nat Med
. 2008 Apr;
14(5):518-27.
PMID: 18438415
Although it is increasingly evident that cancer is influenced by signals emanating from tumor stroma, little is known regarding how changes in stromal gene expression affect epithelial tumor progression. We...